Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase I/II study of VUM02 injection in steroid-refractory acute graft-versus-host disease
CTR20241694Phase 2Active
- Sponsor
- Wuhan Optics Valley Zhongyuan Pharmaceutical
- Start
- Oct 2025
- Modality
- Stem Cell Therapies → Cell Therapies
- Countries
- 1
01
Overview
A Phase 2 trial of VUM02 in Acute Graft-Versus-Host Disease (aGvHD), sponsored by Wuhan Optics Valley Zhongyuan Pharmaceutical. Started Oct 2025; status: active.
02
Drugs
VUM02
03
Conditions
Acute Graft-Versus-Host Disease (aGvHD)
Beyond the preview
Go deeper on CTR20241694.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20241694.